Clinical trial
Cilengitide in Treating Children With Refractory Primary Brain Tumors
NCT00063973 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00063973 |
|---|---|
| Title | Cilengitide in Treating Children With Refractory Primary Brain Tumors |
| Official title | Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma and 16 more |
| Intervention type | Drug, Other |
| Interventions | cilengitide, laboratory biomarker analysis |
| Enrollment | 24 |
| Start date | Jul 1, 2003 |
| Primary completion | Mar 1, 2008 |
| First posted | Jul 9, 2003 |
| Last update posted | Sep 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: